{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:02:49Z","timestamp":1790622169409,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003356","name":"Gazi \u00dcniversitesi","doi-asserted-by":"publisher","award":["01\/2020-18"],"award-info":[{"award-number":["01\/2020-18"]}],"id":[{"id":"10.13039\/501100003356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clbc.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T02:10:15Z","timestamp":1660961415000},"page":"e901-e915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-7743","authenticated-orcid":false,"given":"Elif","family":"Acar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcldal","family":"Esenda\u011fl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2022.08.005_bib0001","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 2","key":"10.1016\/j.clbc.2022.08.005_bib0002","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2022.08.005_bib0003","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.clbc.2022.08.005_bib0004","doi-asserted-by":"crossref","unstructured":"Emens LA, Braiteh FS, Cassier P, et\u00a0al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). AACR; 2015. doi:10.1158\/1538-7445.AM2015-2859","DOI":"10.1158\/1538-7445.AM2015-2859"},{"key":"10.1016\/j.clbc.2022.08.005_bib0005","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1758834016658423","article-title":"Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond","volume":"8","author":"Migali","year":"2016","journal-title":"rapeutic advances med oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0006","series-title":"Cellular and Molecular Immunology E-Book","author":"Abbas","year":"2014"},{"key":"10.1016\/j.clbc.2022.08.005_bib0007","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"Pt 2","key":"10.1016\/j.clbc.2022.08.005_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3389\/fimmu.2016.00244","article-title":"Yamazaki-Itoh R. tertiary lymphoid organs in cancer tissues","volume":"7","author":"Hiraoka","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0011","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures","volume":"26","author":"Dieu-Nosjean","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0012","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3889\/oamjms.2018.341","article-title":"Tertiary lymphoid structures in colorectal cancers and their prognostic value","volume":"6","author":"Trajkovski","year":"2018","journal-title":"Open access Macedonian J med sci"},{"key":"10.1016\/j.clbc.2022.08.005_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2022.08.005_bib0014","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1634\/theoncologist.2017-0029","article-title":"Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers","volume":"22","author":"Liu","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2022.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","article-title":"The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer","volume":"68","author":"Sofopoulos","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clbc.2022.08.005_bib0016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0018","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7150\/jca.17437","article-title":"Strong correlation of indoleamine 2,3-dioxygenase 1 expression with basal-like phenotype and increased lymphocytic infiltration in triple-negative breast cancer","volume":"8","author":"Kim","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.4847","article-title":"The molecular basis of breast cancer pathological phenotypes","volume":"241","author":"Heng","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1490854","article-title":"Tumor mutational burden is a determinant of immune-mediated survival in breast cancer","volume":"7","author":"Thomas","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clbc.2022.08.005_bib0022","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fimmu.2019.00757","article-title":"Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer","volume":"10","author":"Liubomirski","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0023","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1148\/radiol.2018171118","article-title":"Receptor-based surrogate subtypes and discrepancies with breast cancer intrinsic subtypes: implications for image biomarker development","volume":"289","author":"Jamshidi","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.clbc.2022.08.005_bib0024","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the neoaltto trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0026","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.2147\/CMAR.S201538","article-title":"Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the international immuno-oncology biomarkers working group","volume":"11","author":"Liu","year":"2019","journal-title":"Cancer manage res"},{"key":"10.1016\/j.clbc.2022.08.005_bib0027","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1245\/s10434-017-6332-2","article-title":"Prognostic value of tumor-infiltrating lymphocyte density assessed using a standardized method based on molecular subtypes and adjuvant chemotherapy in invasive breast cancer","volume":"25","author":"Jang","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12885-015-1116-1","article-title":"Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients","volume":"15","author":"Figenschau","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0029","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1309\/AJCPIXUYDVZ0RZ3G","article-title":"Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in her2-positive breast cancer treated with adjuvant trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0030","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jclinpath-2015-203089","article-title":"Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer","volume":"69","author":"Lee","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0031","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10549-016-4095-2","article-title":"PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients","volume":"162","author":"Tsang","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000150","article-title":"Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer","volume":"2","author":"Kitano","year":"2017","journal-title":"ESMO open"},{"key":"10.1016\/j.clbc.2022.08.005_bib0033","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2019.04.010","article-title":"Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study","volume":"114","author":"Noske","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0034","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-013-2581-3","article-title":"The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer","volume":"139","author":"Muenst","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.005_bib0035","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/CAD.0000000000000683","article-title":"Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis","volume":"29","author":"Zhou","year":"2018","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2022.08.005_bib0036","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-016-0783-4","article-title":"An immune stratification reveals a subset of PD-1\/LAG-3 double-positive triple-negative breast cancers","volume":"18","author":"Bottai","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2022.08.005_bib0037","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40425-019-0499-y","article-title":"Prognostic value of CD8\u2009+\u2009PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer","volume":"7","author":"Yeong","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0038","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00262-014-1519-x","article-title":"PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients","volume":"63","author":"Sun","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clbc.2022.08.005_bib0039","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ijc.32785","article-title":"Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival","volume":"147","author":"Tu","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4048\/jbc.2018.21.2.124","article-title":"Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer","volume":"21","author":"Wang","year":"2018","journal-title":"J breast cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106113","article-title":"The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy","volume":"78","author":"Du","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0042","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502128","article-title":"TIM-3 expression in breast cancer","volume":"7","author":"Burugu","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clbc.2022.08.005_bib0043","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4048\/jbc.2018.21.e61","article-title":"T-Cell immunoglobulin mucin 3 expression on tumor infiltrating lymphocytes as a positive prognosticator in triple-negative breast cancer","volume":"21","author":"Byun","year":"2018","journal-title":"J breast cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0044","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3892\/mco.2017.1360","article-title":"T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: Clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes","volume":"7","author":"Zhang","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdw623","article-title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"28","author":"Pruneri","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0046","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","article-title":"Prognostic role of immune infiltrates in breast ductal carcinoma in situ","volume":"177","author":"Chen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2022.08.005_bib0047","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","article-title":"Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast","volume":"31","author":"Toss","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0048","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/his.14055","article-title":"Higher densities of tumour-infiltrating lymphocytes and CD4(+) T cells predict recurrence and progression of ductal carcinoma in situ of the breast","volume":"76","author":"Thike","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.clbc.2022.08.005_bib0049","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12885-018-4013-6","article-title":"Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ","volume":"18","author":"Beguinot","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2022.08.005_bib0051","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/path.1700380202","article-title":"The healing of intra-duct carcinoma of the mamma","volume":"38","author":"Muir","year":"1934","journal-title":"J Pathol Bacteriol"},{"key":"10.1016\/j.clbc.2022.08.005_bib0052","series-title":"Rosen's Breast Pathology","author":"Rosen","year":"2001"},{"key":"10.1016\/j.clbc.2022.08.005_bib0053","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/cam4.715","article-title":"CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous \"healing\" in HER2-positive ductal carcinoma in situ","volume":"5","author":"Morita","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clbc.2022.08.005_bib0055","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ajcp\/aqz020","article-title":"The PD-1\/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the breast","volume":"152","author":"Ubago","year":"2019","journal-title":"Am J Clin Pathol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820922001811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820922001811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:33Z","timestamp":1761513873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820922001811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1526820922001811"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2022.08.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}